Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, explains the role that eosinophils play in everyday health and disease development.
Michael E. Wechsler, MD, a pulmonologist at National Jewish Health and director of the Cohen Family Asthma Institute, explains the role that eosinophils play in everyday health and disease development.
Transcript
What role do eosinophils play in health and different diseases?
So, eosinophils play important roles in both health and disease. In health, they play an important role in terms of an immune response. They play a role in homeostasis. They play a role in terms of growth and development in a variety of different organ systems. In terms of immune function, they play a role in parasite immunity, primarily. That's where we think of them the most, but also their roles in terms of tumor immunity and host protection.
In terms of homeostasis, a play a role in a variety of different tissues, including the lungs, the skin, the airways, and the GI [gastrointestinal] tract. And then, in terms of growth and development, they've actually been shown to play a role in terms of growth and development of mammary glands in particular. So, from those perspectives, eosinophils play an important role in terms of maintaining health.
The issue is that if you have too many eosinophils, they can cause some degree of damage, because eosinophils have a variety of granular proteins that they release, including eosinophilic cationic protein, major basic protein, eosinophil derived neurotoxin, and eosinophilic ascites. And so, if there's specific stimuli by tissue injury, or infections by viruses, or different allergies and those can cause the eosinophils to be activated to release those secretary products. And when eosinophils infiltrate the tissue, then that causes damage to the tissue. We see that in a variety of conditions. Everything from asthma, to sinus disease, to eosinophilic GI disease, inflammatory bowel disease, to other eosinophilic conditions.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More